Questions about authorisation of alteplase for ischaemic stroke
Author:
- 1 August 2014
- journal article
- Published by Elsevier in The Lancet
- Vol. 384 (9944) , 659-660
Abstract
No abstract availableThis publication has 11 references indexed in Scilit:
- Effect of thrombolysis with alteplase within 6 h of acute ischaemic stroke on long-term outcomes (the third International Stroke Trial [IST-3]): 18-month follow-up of a randomised controlled trialThe Lancet Neurology, 2013
- The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trialThe Lancet, 2012
- Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trialsThe Lancet, 2010
- Thrombolysis for acute ischaemic stroke2009
- A Graphic Reanalysis of the NINDS TrialAnnals of Emergency Medicine, 2009
- Thrombolysis with alteplase 3–4·5 h after acute ischaemic stroke (SITS-ISTR): an observational studyThe Lancet, 2008
- Thrombolysis with Alteplase 3 to 4.5 Hours after Acute Ischemic StrokeNew England Journal of Medicine, 2008
- Impact of functional status at six months on long term survival in patients with ischaemic stroke: prospective cohort studiesBMJ, 2008
- Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trialsThe Lancet, 2004
- Tissue Plasminogen Activator for Acute Ischemic StrokeNew England Journal of Medicine, 1995